ERBB2 and breast carcinoma: Using a novel method of data analysis that models the simultaneous growth and regression of tumors using radiographic measurements, we analyzed the data of 393 patients with HR-positive, HER2-negative advanced breast cancer enrolled in PALOMA-3 [9–12, 17, 18].